Moreover, patients with rheumatoid arthritis or psoriasis who were taking anti-TNF therapies showed a decreased risk of developing AD.[14,32,39] Indeed, neuroinflammation is believed to be a founding event in AD, perhaps occuring even prior to Aβ plaque deposition.[40] Consistent with these findings, we showed that NE3107 treatment was associated with marked, albeit statistically non-significant, reductions in plasma TNF-α levels from baseline. Here, TNF is linked to psoriasis.